↓ Cooling
Business
Genentech pays Alector $100M for preclinical Parkinson’s prospect
Genentech’s $100 million upfront for Alector’s preclinical Parkinson’s candidate ignites a multi‑billion licensing race.
Genentech
4 independently detected trends connected to this subject, with the latest coverage first.
What Archynetys tracks about Genentech
This hub groups 4 separate news trends connected to Genentech, spanning August 24, 2026 through October 5, 2026. Each event page combines source coverage, attention velocity and a time-stamped explanation instead of treating every headline as a separate story.
The record below represents 23 article observations and 23 source signals, led by Business coverage. Use it to compare how individual events emerged, spread and changed over time.
◼ Archived
Business
BioNTech-Genentech cancer vax records more deaths than control in scrapped ph. 2 test
BioNTech and Roche have halted a mid-stage cancer vaccine trial after more deaths occurred in the treatment group than in the control group.
◼ Archived
Business
Genentech doubles down on ADC-resistance via $1B DualityBio pact
Genentech's $1B bet on DualityBio's ADC technology signals a major shift in cancer treatment strategies.
◼ Archived
Business
🔮 fades ✓
Roche pens $2.5B pact for Hanmi’s clinical-stage obesity drug targeting less-explored mechanism
Roche’s $2.5 billion pact for Hanmi’s muscle‑sparing obesity drug ignites expectations for a new weight‑loss breakthrough